��������

Shobi A. is the Founder and Chief Executive Officer of Sama Therapeutics since January 2022. Prior experience includes serving as a Consultant in Clinical Pipeline R&D at Biohaven Pharmaceuticals, Director of Clinical & Scientific Operations at Transcend Therapeutics, and Venture Fellow at AlleyCorp. Additionally, Shobi held roles as a Consultant for Program Development at Curebase and Principal Clinical Investigator at nference. Earlier experience includes directing R&D at Amelio and conducting doctoral research at Harvard University. Shobi's educational background includes an MD from Yale School of Medicine, a PhD and MA from Harvard University in Near Eastern Languages & Civilizations, and a BS/BA in Biomedical Engineering and the History of Science, Medicine & Philosophy from The Johns Hopkins University.